WebINC280 是一种高选择性口服小分子 Met 抑制剂,在人体肿瘤模型中具有临床前活性。 本项剂量递增 I 期临床试验旨在评估 INC280 对 Met 相关晚期实体肿瘤患者的治疗效果。 WebApr 10, 2015 · A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as …
Capmatinib (INC280) c-MET Kinase Inhibitor
WebJul 3, 2015 · INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. WebCapmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor INC280 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce … curare wirkungsort
Capmatinib - Wikipedia
WebMay 25, 2024 · 9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b). Here, we report the efficacy and safety of capmatinib in pts with high-level MET-amplified (gene copy number … http://www.btboook.com/43056.html WebMar 1, 2015 · INC280 is an oral, highly selective MET inhibitor that has exhibited preclinical and preliminary clinical anti-tumor activity in various solid tumors. This dose escalation and expansion study was designed to evaluate INC280 safety and efficacy in patients (pts) with advanced MET-dependent solid tumors.Methods : The primary objectives of this ... curariform agents